Search clinical trials for: Gefitnib

Total 353 results

Tan Tock Seng Hospital
AstraZeneca; Singapore Cancer Syndicate.

Unknown

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Liver Cancer

Singapore
Sun Yat-sen University

Unknown

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations. (NEGOTIATE)

Lung Cancer

China
University of Zurich

Completed

Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

Recurrent Glioblastoma

Switzerland
Qilu Pharmaceutical Co., Ltd.

Unknown

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Sun Yat-sen University
Wu Jieping Medical Foundation

Completed

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

Non-small Cell Lung Cancer

China
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Non-small Cell Lung Cancer
AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
NCIC Clinical Trials Group

Completed

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer

Canada
University of Maryland, Baltimore
National Cancer Institute (NCI); University of Maryland Greenebaum Cancer Center

Completed

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Kidney Cancer

United States
Samsung Medical Center

Unknown

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Non-small Cell Lung Cancer

Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada, United Kingdom, Australia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Esophageal Cancer

United States
Duke University
National Cancer Institute (NCI)

Completed

ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse

Brain and Central Nervous System Tumors

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
European Organisation for Research and Treatment...

Completed

Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

Sarcoma

France, Belgium, United Kingdom, Netherlands
European Organisation for Research and Treatment...

Completed

Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy

Breast Cancer

Belgium
University Health Network, Toronto
AstraZeneca

Completed

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

LUNG CANCER

Canada
Tianjin Medical University Cancer Institute and...

Suspended

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
AstraZeneca

Terminated

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Non Small Cell Lung Carcinoma

Italy
AstraZeneca

Completed

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

Non-Metastatic Prostate Cancer

Finland
Baylor Breast Care Center

Terminated

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

BREAST CANCER

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Head and Neck Cancer

United States
Jiangmen Central Hospital

Unknown

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Breast Cancer
Daping Hospital and the Research Institute of Surgery...

Completed

Combination of Metformin With Gefitinib to Treat NSCLC (CGMT)

NSCLC | Advanced Cancer | EGFR Gene Amplification | Stage IV NSCLC | Stage IIIB NSCLC

China
AstraZeneca

Completed

Iressa Expanded Access Program (EAP)

Carcinoma | Neoplasm | Non-small-cell Lung | Metastases

United States
European Organisation for Research and Treatment...

Terminated

Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Italy, Netherlands, Egypt, Belgium, Cyprus
Zhejiang Cancer Hospital

Unknown

Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer

Esophageal Cancer

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

ZD 1839 in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
AstraZeneca

Terminated

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

Brain Neoplasms | Non Small Cell Lung Cancer

Italy
Guangdong Provincial People's Hospital

Unknown

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastasis
Amsterdam UMC, location VUmc

Terminated

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients (IRENE)

Lung Cancer

Netherlands
AstraZeneca

Completed

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment (ICARUS)

Lung Cancer

Italy
Chonnam National University Hospital
AstraZeneca

Completed

Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC) (ReGaiN)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
AstraZeneca

Completed

Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer

Breast Cancer

Sweden, Norway, Denmark
AstraZeneca

Completed

IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma

Cancer of Head and Neck

Spain
AstraZeneca

Completed

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Cancer of Head and Neck | Squamous Cell Cancer

United Kingdom
AstraZeneca

Completed

Open-Label Extension of Other SZ1839 (Iressa) Trials

Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

Colorectal Cancer

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IIIB Non-small Cell Lung Cancer | Anaplastic Thyroid Cancer | Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); AstraZeneca

Terminated

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Lung Cancer

United States
The University of Texas Health Science Center at...
National Cancer Institute (NCI)

Completed

ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States
AstraZeneca

Withdrawn

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Carcinoma, Squamous Cell

Italy
Sun Yat-sen University
Wu Jieping Medical Foundation

Recruiting

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases | EGFR Mutation

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital

Not yet recruiting

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NSCLC

China
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Terminated

Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (ARPEGE)

Brain Metastasis | EGFR-mutated Lung Adenocarcinoma

France
Dana-Farber Cancer Institute
Boston Children's Hospital; Brigham and Women's Hospital

Completed

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Myelogenous Leukemia, Acute

United States
Massachusetts General Hospital

Completed

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States

Search clinical trials for: Gefitnib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations